CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The shift in focus from centralised laboratories to decentralised Point-of-Care testing
4.1.2. Rising prevalence of infectious diseases
4.1.3. Growth in funding for research on infectious disease diagnostics
4.2. Market Restraints & Challenges
4.2.1. Rising healthcare costs limiting the use of novel diagnostic techniques
4.2.2. Inadequate reimbursements
4.3. Market Opportunities
4.3.1. Increasing awareness about personalised medicine
4.3.2. Advances in genomics and proteomics
CHAPTER 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET – BY
PRODUCT & SERVICES
5.1. Services & Software
5.2. Assays, Kits, & Reagents
5.3. Instruments
5.4. Others
CHAPTER 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET – BY
TECHNOLOGY
6.1. Clinical Microbiology
6.2. Immunodiagnostics
6.3. DNA Microarray
6.4. Polymerase Chain Reaction (PCR)
6.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
6.6. DNA Sequencing & Next-Generation Sequencing (NGS)
6.7. Others
CHAPTER 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET – BY
DISEASES TYPE
7.1. Influenza
7.2. Tuberculosis (TB)
7.3. Hospital-Acquired Infections (HAIS)
7.4. Human Papillomavirus (HPV)
7.5. Human Immunodeficiency Virus (HIV)
7.6. Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
7.7. Hepatitis
7.8. Others
CHAPTER 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET - BY END
USER
8.1. Academic/Research Institutes
8.2. Hospital/Clinical Laboratories
8.3. Reference Laboratories
8.4. Physician Offices
8.5. Hospital/Clinical Laboratories
8.6. Others
CHAPTER 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
8.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET -
COMPANY PROFILES
10.1. Roche Diagnostics, Pvt. Ltd.
10.2. Agilent Technologies, Inc.
10.3. Grifols, S.A
10.4. Biomérieux SA
10.5. Abbott Laboratories, Ltd.
10.6. Siemens AG
10.7. Becton, Dickinson and Company
10.8. Hologic, Inc.
10.9. Danaher Corporation
10.10. Qiagen N.V
10.11. Illumina, Inc.
10.12. Diasorin Molecular, LLC
CHAPTER 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET –
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
